PMID 11031273
The dose-finding phase 2 trial randomised 706 adults with obesity, or overweight plus at least one weight-related comorbidity, to once-weekly cagrilintide at 0.3, 0.6, 1.2, 2.4 or 4.5 mg, weekly placebo, or daily liraglutide 3.0 mg as an active comparator, all alongside lifestyle intervention
Patient Education and Safety Guidelines We explain how to use cannabis safely, including dosage, timing, and storage
This is called the gate control theory of pain, and it has solid scientific backing
Don't settle for "off-the-shelf" when you can hunt for high scores on a rig designed by you and hand-assembled by our experts
Molecular cloning, expression and immunolocalization of a novel human cementum-derived protein (CP-23)